and marketingbusiness developmentproduct developmentregulatory affairsmanufacturing and supply chainproduct portfoliorespiratorydermatologypain and inflammationcx productsotc productsother productsproduct developmentinvestorsfinancial reportsannual reportspresentationsrottapharm acquisitionmylan offerrights issuecalendarmtn programmecontactsnewsroomcsrsustainability reportspoliciescommunity involvementcontactscontact us menuabout medaproduct portfolioinvestorsnewsroomcsrcontact us meda is a leading international pharma company with a broad product portfolio mylan s acquisition of meda was completed on august 5 2016 . learn more . topical corporate info meda egm august 25th at 15 00 cet for notice of egm attendance click here in swedish mylan announces public offer to the shareholders of meda financial information interim report january june 2016 interim report january march 2016 latest news about meda our vision and mission product portfolio sales and marketing meda annual general meeting dividend sek 2.50 2016 04 14 meda ab publ agm bulletin meda annual report 2015 quick facts we strive to be a fast growing innovative company that is open to different kinds of commercial models and that will be market leading in certain therapy areas with prescription and otc products . we are dedicated to providing products that serve society by increasing the well being and quality of life of individuals . as a company our aim is to attract the best talent and reward our employees for outstanding performance . maintaining our excellent reputation is vital to us . our products meda has a well diversified product portfolio a global presence and is represented within all areas of pharmaceuticals specialty products cx and otc view product portfolio cb12 is a powerful unique and patented mouth rinse that ensures not only first class breath but also provides a daily shot of confidence . every day and all day cb12 provides 12 hours of protection . endwarts is an effective treatment for self removal of warts on hands feet and the body . dymista is a new nasal spray for the treatment of allergic rhinitis . dymista is a novel formulation of azelastine and fluticasone propionate . zyclara is an immune response modulator agent imiquimod 3 75 % for the treatment of large areas of actinic keratosis . elidel is a steroid free drug pimecrolimus for the treatment of atopic dermatitis which is a chronic recurring inflammatory skin disease . this website is intended for people seeking information on meda ab s global operations . we also have national marketing sites . links to these are under meda worldwide at the top of the page . postaddress.meda ab box 906 se 170 09 solna sweden visitors.pipers v g 2a tel 46 8 630 19 00fax 46 8 630 19 50e mail info remove this.meda.se privacy policyterms of usecookiescopyright copyright meda